|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Fibromyalgia - Potentially Lucrative Market Soon To Become Reality
Datamonitor, May 2007, Pages: 163
Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical profession and the pharmaceutical industry. Currently, there are no drugs licensed to treat fibromyalgia in the US, Japan or Europe.
Scope of this title:
Analysis of the patient potential, main unmet needs, and clinical trial design in fibromyalgia, with an estimation of market size. Insight into current treatment controversies, including referral and prescribing patterns across the seven major markets. Detailed profiles of Cymbalta, Lyrica, and milnacipran for use in fibromyalgia, with indication-specific sales forecasts of these drugs to 2016. Discussion of key fibromyalgia market drivers, such as strategies that improve public awareness and physician education.
Highlights of this title:
Following FDA approvals, we foresee a dramatic rise in market value resulting from an upsurge in diagnosis and treatment rates. Estimated at $367m in 2006 in the US and 5EU, the market is forecast to grow to $1.7 billion in 2016. Commercial success of new fibromyalgia brands will encourage other companies to consider investment, and will see the R&D pipeline for new therapies increase over the coming years. A defined regulatory pathway will also attract future investors. Polypharmacotherapy will become commonplace in fibromyalgia management and Lyrica with Cymbalta will be a popular combination. This is good news for Lilly and Pfizer as it will effectively expand their market by reducing competition.
Reasons to order your copy:
Quantify the future market size in order to weigh up the risk of investing in fibromyalgia or to validate internal forecasts for pipeline products. Gain insight into opinion leaders thoughts on the major opportunities and challenges facing the fibromyalgia market. Assess the six major market (US and 5EU) sales forecasts of key late-stage pipeline drugs to 2016; and examine their clinical and commercial potential
Customers who bought this item also bought
Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion
Stakeholder Insight: Fibromyalgia - Substantial Growth Opportunity for SNRI Antidepressants
Fibromyalgia Market Forecast
European Markets for Fibromyalgia Syndrome
Target Product Profiles 2008: Physician Insights on Key Attributes - Fibromyalgia
Healing Fibromyalgia: The Three-Step Solution
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
The Global Pain Therapeutics Market, 3rd Edition - Market Analysis, R&D Pipelines and Competitive Landscape
The Global Pain Therapeutics Market: Market Analysis, R&D Pipelines and Competitive Landscape
Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities
Antibody drug conjugates for cancer treatment: Clinical Trial Pipeline
Commercial Insight: Pain Market Overview - Non-traditional Analgesics and Opioid Reformulations to Sustain Sector Growth
|
|
|
|
